Reduction of human recombinant type II phospholipase A2 and prostaglandin F(2α) release by microtubule depolymerizing agents

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 3, 1999, Pages 230-235

  Munns, M J ^a   King, R G ^b   Rice, Greg E ^a,c  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chinese hamster ovary cells; Colchicine; Microtubule; Phospholipase A2; Placenta; Prostaglandin F(2 ); Taxol; Tubulazole

Indexed keywords

ANTIINFLAMMATORY AGENT; COLCHICINE; PACLITAXEL; PHOSPHOLIPASE A2; PROSTAGLANDIN F2 ALPHA; TUBULAZOLE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHO CELL; ENZYME INHIBITION; ENZYME RELEASE; EXPLANT; HUMAN; HUMAN TISSUE; INFLAMMATION; MICROTUBULE ASSEMBLY; PLACENTA; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION;

ANIMALS; CELL-FREE SYSTEM; CHO CELLS; COLCHICINE; CRICETINAE; DINOPROST; DIOXOLANES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GOUT SUPPRESSANTS; HUMANS; MICROTUBULES; PHOSPHOLIPASES A; PLACENTA; RADIOIMMUNOASSAY; RECOMBINANT PROTEINS;

EID: 0033028061     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.03020.x     Document Type: Article

References (31)

1. 2 in the pathobiology of disease. Lab. Invest. 1986; 55: 391-404.
2. 2. Rice GE. Glycerophospholipid metabolism and human labour. Reprod. Fertil. Dev. 1995; 7: 613-22.
3. 2. Biochim. Biophys. Acta 1993; 117: 217-31.
4. 4. Levy M, Spino M, Read SE. Colchicine: A state-of-the-art review. Pharmacotherapy 1991; 11: 196-211.
5. 5. Asako H, Kubes P, Baethge BA, Wolf RE, Granger DN. Colchicine and methotrexate reduce leukocyte adherence and emigration in rat mesenteric venules. Inflammation 1992; 16: 45-56.
6. 2 activity in the zymosan rat air pouch model of inflammation. Br. J. Pharmacol. 1996; 117: 1773-9.
7. 7. Malawista SE. The action of colchicine in acute gouty arthritis. Arthritis Rheum. 1975; 18: 835-46.
8. 8. Ding AH, Porteu F, Sanchez E, Nathan CF. Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerising agents. J. Exp. Med. 1990; 171: 715-27.
9. 9. Cox JB, Snyderman R, Murray JJ. Inhibition of 5-lipoxygenase translocation and activation in human neutrophils by microtubule disruption. Clin. Res. 1987; 35: 472A (Abstract).
10. 10. Wacker I, Kaether C, Kromer A, Migala A, Almers W, Gerdes H. Microtubule-dependent transport of secretory vesicles visualized in real time with a GFP-tagged secretory protein. J. Cell Sci. 1997; 110: 1453-63.
11. 11. Geuens GMA, Nuydens RM, Willebrords RE et al. Effects of tubulazole on the microtubule system of cells in culture and in vivo. Cancer Res. 1985; 45: 733-42.
12. 12. Lafont F, Simons K. The role of microtubule-based motors in the exocytic transport of polarised cells. Semin. Cell Dev. Biol. 1966; 7: 343-55.
13. 2 in rat vascular smooth muscle cells and its possible relationship to eicosanoid formation. Biochim. Biophys. Acta 1991; 1082: 285-92.
14. 2. Lab. Invest. 1997; 76: 171-8.
15. 15. Gebert CA, Gray PP. Expression of FSH in CHO cells. I. Comparison of promoter types and effects of their respective inducers. Cytotechnology 1994; 14: 39-45.
16. 2 in human gestational tissues: Subcellular distribution of placental immunoactivity and catalytic activity. Biochim. Biophys. Acta 1993; 1166: 77-83.
17. 2 in human gestational tissues: Extractable immuno-and enzymatic activity in fetal membranes. Biochim. Biophys. Acta 1993; 1170: 314-20.
18. 2 in arthritis plasma using a newly developed sandwich ELISA. Br. J. Rheumatol. 1992; 31: 175-8.
19. 19. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72 248-54.
20. 20. Bartlett MS, Kendall DG. The statistical analysis of variance: Heterogeneity and the logarithmic transformation. J. R. Statist. Soc. Suppl. 1946; 8: 128-38.
21. 21. Hoshino H, Tamaki A, Yagura T. Process of dispersion and fragmentation of Golgi complex by microtubule bundles formed in taxol treated HeLa cells. Cell Struct. Funct. 1997; 22: 325-34.
22. 22. Chaldakov GN, Vankov VN. Morphological aspects of secretion in the arterial smooth muscle cell, with special reference to the Golgi complex and microtubular cytoskeleton. Atherosclerosis 1986; 61: 175-92.
23. 2) activity in gerbil brain: Characterisation of cytosolic and membrane associated forms and effects of ischemia and reperfusion on enzymatic activity. J. Lipid Med. 1993; 6: 457-71.
24. 24. Grosfils K, Gomez F, Dehaye JP. Inhibition by mepacrine of amylase secretion from intact and permeabilized rat pancreatic acini. Biochem. Biophys. Res. Commun. 1992; 184: 408-11.
25. 2 inhibitors suppressed lysophosphatidylserine dependent degranulation of rat peritoneal cells. Biochem. Biophys. Res. Commun. 1991; 181: 714-21.
26. 26. Walter RJ, Berlin RD, Pfeiffer JR, Oliver JM. Polarisation of endocytosis and receptor topography on cultured macrophages. J. Cell Biol. 1980; 86: 199-211.
27. 27. Palade G. Intracellular aspects of the process of protein synthesis. Science 1975; 189: 347-58.
28. 28. Berlin RD, Fera JP. Changes in membrane microviscosity associated with phagocytosis: effects of colchicine. Proc. Natl Acad. Sci. USA 1977; 74: 1072-6.
29. 29. De Petris S. Inhibition and reversal of capping by cytochalasin B, vinblastine and colchicine. Nature 1974; 250: 54-5.
30. 30. Wunderlich F, Muller R, Speth V. Direct evidence for a colchicine-induced impairment in the mobility of membrane components. Science 1973; 182: 1136-8.
31. 31. Berlin RD, Oliver JM, Ukena TE, Yin HH. Control of cell surface topography. Nature 1974; 247: 45-6.